Clinical Trials
10 trialsNCT00684385 2019-03-14
An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck
AstraZeneca
Approved for marketing
NCT00206219 2011-01-27
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)
AstraZeneca
Phase 3 Completed
NCT00233636 2011-01-27
Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Phase 2 Withdrawn
NCT00242762 2011-01-27
ZD1839 (IRESSAâ„¢) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer
AstraZeneca
Phase 2 Completed
NCT00681967 2010-09-23
IRESSA&H&N
AstraZeneca
Phase 1 Completed
NCT00229723 2009-08-04
IRESSAâ„¢ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 2 Completed
NCT00242749 2009-04-23
IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma
AstraZeneca
Phase 2 Completed
NCT00255476 2009-04-23
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
AstraZeneca
Phase 2 Completed
NCT00228488 2007-12-19
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma
AstraZeneca
Phase 2 Completed
NCT00239304 2007-12-18
Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer
AstraZeneca
Phase 1/2 Completed